What was the market valuation of bronchodilators in the US in 2024?

The market valuation of bronchodilators in the US was $7.5 Billion in 2024. Read More

What is the projected market valuation for bronchodilators in the US by 2035?

The projected market valuation for bronchodilators in the US is $13.3 Billion by 2035. Read More

What is the expected CAGR for the US bronchodilators market from 2025 to 2035?

The expected CAGR for the US bronchodilators market during the forecast period 2025 - 2035 is 5.35%. Read More

Which drug type segment is projected to have the highest growth in the US bronchodilators market?

The Combination Drugs segment is projected to grow from $3.0 Billion to $5.3 Billion during the forecast period. Read More

What are the projected values for short-acting and long-acting bronchodilators by 2035?

Short-Acting Bronchodilators are projected to reach $5.0 Billion, while Long-Acting Bronchodilators may reach $8.3 Billion by 2035. Read More

Which disease segment is expected to dominate the US bronchodilators market?

The COPD segment is expected to dominate, growing from $4.0 Billion to $7.0 Billion by 2035. Read More

What are the key players in the US bronchodilators market?

Key players in the US bronchodilators market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Merck & Co. Read More

How do the oral and parenteral routes of administration compare in the US bronchodilators market?

Both the Oral and Parenteral routes of administration are projected to grow from $3.75 Billion to $6.65 Billion by 2035. Read More

What is the market size for anticholinergics in the US bronchodilators market?

The Anticholinergics segment is projected to grow from $1.5 Billion to $2.5 Billion during the forecast period. Read More

What does the growth of the bronchodilators market indicate about respiratory health trends in the US?

The growth of the bronchodilators market suggests an increasing focus on respiratory health, particularly in managing conditions like asthma and COPD. Read More

US Bronchodilators Market

ID: MRFR/HC/18050-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Bronchodilators Market Research Report By Drug Type (Adrenergic drugs, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs), By Disease (Asthma, COPD, Others), By Mode of Action (Short-Acting Bronchodilators, Long-Acting Bronchodilators) and By Route of Administration (Oral, Parenteral) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Type (USD Billion)
  1. 4.1.1 Adrenergic drugs
  2. 4.1.2 Anticholinergics
  3. 4.1.3 Phosphodiesterase Inhibitor
  4. 4.1.4 Combination Drugs
2. 4.2 Chemicals and Materials, BY Disease (USD Billion)
  1. 4.2.1 Asthma
  2. 4.2.2 COPD
  3. 4.2.3 Others
3. 4.3 Chemicals and Materials, BY Mode of Action (USD Billion)
  1. 4.3.1 Short-Acting Bronchodilators
  2. 4.3.2 Long-Acting Bronchodilators
4. 4.4 Chemicals and Materials, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Parenteral
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AstraZeneca (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Mylan (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DRUG TYPE
3. 6.3 US MARKET ANALYSIS BY DISEASE
4. 6.4 US MARKET ANALYSIS BY MODE OF ACTION
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 CHEMICALS AND MATERIALS, BY DISEASE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY DISEASE, 2024 TO 2035 (USD Billion)
16. 6.16 CHEMICALS AND MATERIALS, BY MODE OF ACTION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY MODE OF ACTION, 2024 TO 2035 (USD Billion)
18. 6.18 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.2.3 BY MODE OF ACTION, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Type (USD Billion, 2025-2035)

Adrenergic drugs
Anticholinergics
Phosphodiesterase Inhibitor
Combination Drugs

Chemicals and Materials By Disease (USD Billion, 2025-2035)

Asthma
COPD
Others

Chemicals and Materials By Mode of Action (USD Billion, 2025-2035)

Short-Acting Bronchodilators
Long-Acting Bronchodilators

Chemicals and Materials By Route of Administration (USD Billion, 2025-2035)

Oral
Parenteral

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓